Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camille Sibertin-Blanc

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
La Revue Du Praticien|February 26, 2019
[Gastric tumors]Camille Sibertin-Blanc, Laetitia Dahan, Jean-François Seitz
BMC Research Notes|November 20, 2013
Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: a case reportCamille Sibertin-Blanc, Emmanuelle Norguet, Muriel Duluc, et al.
Expert Opinion on Biological Therapy|March 15, 2016
Monoclonal antibodies for treating gastric cancer: promises and pitfallsCamille Sibertin-Blanc, Joseph Ciccolini, Emmanuelle Norguet, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 25, 2015
Vascular Endothelial Growth Factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancerCamille Sibertin-Blanc, Julien Mancini, Aurélie Fabre, et al.
Health and Quality of Life Outcomes|April 29, 2017
Nutritional status and quality of life of cancer patients needing exclusive chemotherapy: a longitudinal studySebastien Salas, Sophie Mercier, Benjamin Moheng, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 22, 2017
Clinical outcome after biliary drainage for metastatic colorectal cancer: Survival analysis and prognostic factorsFloriane Sellier, Erwan Bories, Camille Sibertin-Blanc, et al.
Therapeutic Advances in Medical Oncology|January 5, 2023
Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trialBernadette de Rauglaudre, Camille Sibertin-Blanc, Aurélie Fabre, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
La Revue Du Praticien|February 26, 2019
[Gastric tumors]Camille Sibertin-Blanc, Laetitia Dahan, Jean-François Seitz
BMC Research Notes|November 20, 2013
Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: a case reportCamille Sibertin-Blanc, Emmanuelle Norguet, Muriel Duluc, et al.
Expert Opinion on Biological Therapy|March 15, 2016
Monoclonal antibodies for treating gastric cancer: promises and pitfallsCamille Sibertin-Blanc, Joseph Ciccolini, Emmanuelle Norguet, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 25, 2015
Vascular Endothelial Growth Factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancerCamille Sibertin-Blanc, Julien Mancini, Aurélie Fabre, et al.
Health and Quality of Life Outcomes|April 29, 2017
Nutritional status and quality of life of cancer patients needing exclusive chemotherapy: a longitudinal studySebastien Salas, Sophie Mercier, Benjamin Moheng, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 22, 2017
Clinical outcome after biliary drainage for metastatic colorectal cancer: Survival analysis and prognostic factorsFloriane Sellier, Erwan Bories, Camille Sibertin-Blanc, et al.
Therapeutic Advances in Medical Oncology|January 5, 2023
Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trialBernadette de Rauglaudre, Camille Sibertin-Blanc, Aurélie Fabre, et al.
Pageof 1